Nearly all of Latin America was excluded from the deal, sparking concern the world is missing a critical opportunity to stop ...

Gilead Sciences, Inc. GILD entered into an exclusive option and license agreement with Tubulis, a Germany-based biotech ...

For oral medications that prevent new HIV infection to be effective, the patient must take certain actions, including ...

A recent phase 3 trial found that twice-yearly injections of Lenacapavir reduce the risk of contracting HIV by 96%. | Drug ...